Focused on advancing genetic medicines for neuromuscular and cardiac rare diseases
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreich’s ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Disease-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases.
Guiding Principles
Solid is purpose-built to identify and develop the most promising approaches to address these diseases at all stages.
Singular Focus
We are focused on developing transformative treatments to improve the lives of patients with neuromuscular and cardiac diseases
Patient Centric
We start with patients and their unmet needs.
Collaboration
We are working collectively with all stakeholders — industry, academia, government and community — to advance our gene therapy candidates to better understand their potential to benefit patients.
Center of Excellence
We are a catalyst bringing together the best knowledge to address all aspects of these diseases.